Pritelivir - AiCuris
Alternative Names: AIC-316; BAY 57-1293Latest Information Update: 29 Oct 2025
At a glance
- Originator Bayer
- Developer AiCuris
- Class Amides; Antivirals; Pyridines; Small molecules; Thiazoles
- Mechanism of Action DNA helicase-primase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Herpes simplex virus infections
- Phase II Herpes labialis; Herpes simplex virus type 2 infections
Most Recent Events
- 20 Oct 2025 Efficacy and adverse events data from a phase III PRIOH-1 trial in Herpes simplex virus infections released by AiCuris
- 16 Oct 2025 AiCuris announced the intention to submit NDA to the US FDA for Herpes simplex virus infections in 2026
- 16 Oct 2025 Efficacy and adverse events data from a phase III PRIOH-1 trial in Herpes simplex virus infections released by AiCuris